$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2016 Form 10-K Financial Statement

#000143853317000005 Filed on March 01, 2017

Income Statement

Concept	2016	2015 Q4	2015 Q3
Revenue	$133.6M	$30.45M	$28.01M
YoY Change	33.74%	116.17%	235.47%
Cost Of Revenue	$4.554M	$760.0K	$513.0K
YoY Change	108.42%	123.53%	159.09%
Gross Profit	$129.0M	$29.69M	$27.49M
YoY Change	32.07%	115.93%	237.33%
Gross Profit Margin	96.59%	97.51%	98.17%
Selling, General & Admin	$91.94M	$18.95M	$22.31M
YoY Change	15.59%	2.65%	28.41%
% of Gross Profit	71.25%	63.83%	81.14%
Research & Development	$70.82M	$15.37M	$14.06M
YoY Change	40.45%	8.32%	11.21%
% of Gross Profit	54.89%	51.77%	51.16%
Depreciation & Amortization	$16.14M	$3.970M	$3.880M
YoY Change	20.48%	113.44%	109.73%
% of Gross Profit	12.5%	13.37%	14.11%
Operating Expenses	$191.8M	$45.65M	$48.50M
YoY Change	27.33%	39.26%	60.52%
Operating Profit	-$58.21M	-$15.20M	-$20.50M
YoY Change	14.71%	-18.68%	-6.27%
Interest Expense	$4.700M	-$4.210M	-$695.0K
YoY Change	-38.96%	-59.24%	-73.56%
% of Operating Profit
Other Income/Expense, Net	$632.0K	$2.210M	$164.8M
YoY Change	-99.6%	-121.39%	4140.67%
Pretax Income	-$57.58M	-$12.99M	$144.3M
YoY Change	-154.6%	-55.23%	-902.78%
Income Tax	-$9.679M	-$10.53M	$38.76M
% Of Pretax Income			26.85%
Net Earnings	-$47.90M	-$2.469M	$105.6M
YoY Change	-140.86%	-91.49%	-687.2%
Net Earnings / Revenue	-35.86%	-8.11%	377.0%
Basic Earnings Per Share	-$1.29	-$0.07	$2.95
Diluted Earnings Per Share	-$1.29	-$0.14	$1.78
COMMON SHARES
Basic Shares Outstanding	37.00M shares	36.15M shares	35.74M shares
Diluted Shares Outstanding	38.29M shares		42.75M shares

Balance Sheet

Concept	2016	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$255.9M	$229.6M	$235.3M
YoY Change	11.45%	727.1%	522.43%
Cash & Equivalents	$41.00M	$37.81M	$140.6M
Short-Term Investments	$214.9M	$191.8M	$94.68M
Other Short-Term Assets	$8.300M	$10.50M	$2.000M
YoY Change	-20.95%	1212.5%	-13.04%
Inventory	$2.800M	$2.536M	$2.650M
Prepaid Expenses
Receivables	$18.50M	$12.46M	$13.50M
Other Receivables	$46.90M	$46.80M	$46.50M
Total Short-Term Assets	$332.4M	$301.9M	$300.0M
YoY Change	10.1%	708.73%	560.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.600M	$428.0K	$478.0K
YoY Change	550.0%	-36.21%	-20.33%
Goodwill		$936.0K	$936.0K
YoY Change		0.0%
Intangibles		$161.5M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.400M	$1.859M	$2.006M
YoY Change	289.47%	-17.92%	-12.78%
Total Long-Term Assets	$192.9M	$210.3M	$211.7M
YoY Change	-8.32%	114.32%	110.62%
TOTAL ASSETS
Total Short-Term Assets	$332.4M	$301.9M	$300.0M
Total Long-Term Assets	$192.9M	$210.3M	$211.7M
Total Assets	$525.3M	$512.3M	$511.6M
YoY Change	2.54%	278.14%	250.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.500M	$7.639M	$4.893M
YoY Change	-1.32%	7.23%	-56.7%
Accrued Expenses	$23.50M	$23.82M	$22.32M
YoY Change	26.34%	-14.57%	90.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due			$1.000M
YoY Change			-33.33%
Total Short-Term Liabilities	$83.30M	$86.98M	$101.9M
YoY Change	-4.25%	-19.12%	107.63%
LONG-TERM LIABILITIES
Long-Term Debt	$44.40M	$43.80M	$43.70M
YoY Change	1.37%	1.15%	1.39%
Other Long-Term Liabilities	$83.40M	$3.066M	$13.92M
YoY Change	45.8%	89.61%	-78.16%
Total Long-Term Liabilities	$127.8M	$3.066M	$13.92M
YoY Change	26.53%	89.61%	-86.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.30M	$86.98M	$101.9M
Total Long-Term Liabilities	$127.8M	$3.066M	$13.92M
Total Liabilities	$217.5M	$212.3M	$220.6M
YoY Change	2.45%	22.91%	41.33%
SHAREHOLDERS EQUITY
Retained Earnings		-$65.15M	-$62.68M
YoY Change		-63.64%
Common Stock		$365.8M	$353.8M
YoY Change		159.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00	$0.00
YoY Change		-100.0%
Treasury Stock Shares		0.000 shares	0.000 shares
Shareholders Equity	$307.8M	$300.0M	$291.0M
YoY Change
Total Liabilities & Shareholders Equity	$525.3M	$512.3M	$511.6M
YoY Change	2.54%	278.14%	250.67%

Cashflow Statement

Concept	2016	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	-$47.90M	-$2.469M	$105.6M
YoY Change	-140.86%	-91.49%	-687.2%
Depreciation, Depletion And Amortization	$16.14M	$3.970M	$3.880M
YoY Change	20.48%	113.44%	109.73%
Cash From Operating Activities	-$3.441M	-$3.550M	$1.590M
YoY Change	147.73%	-60.95%	-110.26%
INVESTING ACTIVITIES
Capital Expenditures	$1.428M	-$1.720M	-$3.880M
YoY Change	6390.91%	2050.0%	2486.67%
Acquisitions	$615.0K
YoY Change	-98.16%
Other Investing Activities	$22.29M	-$98.74M	$55.01M
YoY Change	-130.3%	-4916.59%	-2995.26%
Cash From Investing Activities	$10.37M	-$100.5M	$51.12M
YoY Change	-112.87%	-5199.49%	-2581.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net	$0.00
YoY Change
Cash From Financing Activities	-$3.849M	1.230M	-39.87M
YoY Change	-103.79%	-332.08%	-1226.27%
NET CHANGE
Cash From Operating Activities	-$3.441M	-3.550M	1.590M
Cash From Investing Activities	$10.37M	-100.5M	51.12M
Cash From Financing Activities	-$3.849M	1.230M	-39.87M
Net Change In Cash	$3.080M	-102.8M	12.84M
YoY Change	-84.29%	1243.53%	-191.58%
FREE CASH FLOW
Cash From Operating Activities	-$3.441M	-$3.550M	$1.590M
Capital Expenditures	$1.428M	-$1.720M	-$3.880M
Free Cash Flow	-$4.869M	-$1.830M	$5.470M
YoY Change	245.07%	-79.69%	-135.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38093583	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	576730241	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016	dei	Trading Symbol TradingSymbol	rtrx
CY2015Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	3158000	USD
CY2016Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	6967000	USD
CY2015Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	964000	USD
CY2016Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	2490000	USD
CY2015Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	4281000	USD
CY2016Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	7311000	USD
CY2015Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3586000	USD
CY2016Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3333000	USD
CY2015Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8885000	USD
CY2016Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8068000	USD
CY2014	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	0	USD
CY2015	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	8219000	USD
CY2016	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	11206000	USD
CY2015Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	4688000	USD
CY2016Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	5766000	USD
CY2015Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	13754000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	16150000	USD
CY2015Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	45267000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	71328000	USD
CY2014	rtrx	Adjustment In Connection With August2013 Private Placement AdjustmentInConnectionWithAugust2013PrivatePlacement	272000	USD
CY2014	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2015	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2016	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	2025000	USD
CY2014	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
CY2015	rtrx	Bargain Purchase Gain BargainPurchaseGain	49063000	USD
CY2016	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
CY2014	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	0	USD
CY2015	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	490000	USD
CY2016	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	2571000	USD
CY2014	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2015	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2016	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	-1655000	USD
CY2014	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2015	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2016	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2014	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0740
CY2015	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	0.1089
CY2016	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0110
CY2014	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	0	USD
CY2015	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13778000	USD
CY2016	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	18383000	USD
CY2015Q4	rtrx	Contractual Obligation Due In Rolling After Year Five ContractualObligationDueInRollingAfterYearFive	9420000	USD
CY2015Q4	rtrx	Contractual Obligation Due In Rolling Year Four And Five ContractualObligationDueInRollingYearFourAndFive	7324000	USD
CY2015Q4	rtrx	Contractual Obligation Due In Rolling Year Two And Three ContractualObligationDueInRollingYearTwoAndThree	57265000	USD
CY2015Q4	rtrx	Contractual Obligation Next Rolling Twelve Months ContractualObligationNextRollingTwelveMonths	10644000	USD
CY2014	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-2460000	USD
CY2015	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-15573000	USD
CY2016	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-22661000	USD
CY2015Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	21575000	USD
CY2016Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	32792000	USD
CY2015Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	-17348000	USD
CY2016Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	9155000	USD
CY2015Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	29095000	USD
CY2016Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	14547000	USD
CY2015Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	218000	USD
CY2016Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2014	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	0	USD
CY2015	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	1050000	USD
CY2016	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	0	USD
CY2014	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
CY2015	rtrx	Early Payment Penalty EarlyPaymentPenalty	2250000	USD
CY2016	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
CY2014	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2015	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	-0.1604
CY2016	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2014	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	31762000	USD
CY2015	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	28012000	USD
CY2016	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	20720000	USD
CY2014	rtrx	Finance Expense FinanceExpense	4721000	USD
CY2015	rtrx	Finance Expense FinanceExpense	600000	USD
CY2016	rtrx	Finance Expense FinanceExpense	0	USD
CY2014	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	0	USD
CY2015	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	140004000	USD
CY2016	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	0	USD
CY2014	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	0	USD
CY2015	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	914000	USD
CY2016	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	0	USD
CY2014	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-6018000	USD
CY2015	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	0	USD
CY2016	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-5212000	USD
CY2015	rtrx	Note Payable Entered Into Upon Consummation Of An Entity NotePayableEnteredIntoUponConsummationOfAnEntity	0	USD
CY2014	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2015	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1267000	USD
CY2016	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1927000	USD
CY2014	rtrx	Kyalin Payments KyalinPayments	1000000	USD
CY2014	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2015	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2016	rtrx	Legal Accrual Reversal LegalAccrualReversal	2967000	USD
CY2014	rtrx	Loss On Impairment Of Cost Method Purchase LossOnImpairmentOfCostMethodPurchase	400000	USD
CY2015	rtrx	Loss On Impairment Of Cost Method Purchase LossOnImpairmentOfCostMethodPurchase	0	USD
CY2016	rtrx	Loss On Impairment Of Cost Method Purchase LossOnImpairmentOfCostMethodPurchase	0	USD
CY2014	rtrx	Note Payable Entered Into Upon Consummation Of An Entity NotePayableEnteredIntoUponConsummationOfAnEntity	31283000	USD
CY2015	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2016	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2014	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	93000	USD
CY2015	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
CY2016	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	115000	USD
CY2014	rtrx	Present Value Of Guaranteed Minimum Royalty Payable To Sellers Of An Entity PresentValueOfGuaranteedMinimumRoyaltyPayableToSellersOfAnEntity	11850000	USD
CY2015	rtrx	Present Value Of Guaranteed Minimum Royalty Payable To Sellers Of An Entity PresentValueOfGuaranteedMinimumRoyaltyPayableToSellersOfAnEntity	0	USD
CY2016	rtrx	Present Value Of Guaranteed Minimum Royalty Payable To Sellers Of An Entity PresentValueOfGuaranteedMinimumRoyaltyPayableToSellersOfAnEntity	0	USD
CY2014	rtrx	Proceeds From Securities Sold Not Yet Purchased ProceedsFromSecuritiesSoldNotYetPurchased	7500000	USD
CY2015	rtrx	Proceeds From Securities Sold Not Yet Purchased ProceedsFromSecuritiesSoldNotYetPurchased	0	USD
CY2016	rtrx	Proceeds From Securities Sold Not Yet Purchased ProceedsFromSecuritiesSoldNotYetPurchased	0	USD
CY2014	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2014	rtrx	Present Value Of Contingent Consideration Payable To Sellers PresentValueOfContingentConsiderationPayableToSellers	12800000	USD
CY2016	rtrx	Note Payable Entered Into Upon Consummation Of An Entity NotePayableEnteredIntoUponConsummationOfAnEntity	0	USD
CY2016Q4	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
CY2015	rtrx	Option Inducement Liability Reversaland Adjustments OptionInducementLiabilityReversalandAdjustments	3840000	USD
CY2014	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	0.0000
CY2015	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0079
CY2016	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0309
CY2014	rtrx	Payment Of Acquisition Related Contingent Consideration PaymentOfAcquisitionRelatedContingentConsideration	1163000	USD
CY2015	rtrx	Payment Of Acquisition Related Contingent Consideration PaymentOfAcquisitionRelatedContingentConsideration	3938000	USD
CY2016	rtrx	Payment Of Acquisition Related Contingent Consideration PaymentOfAcquisitionRelatedContingentConsideration	12356000	USD
CY2014	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	0	USD
CY2015	rtrx	Present Value Of Contingent Consideration Payable To Sellers PresentValueOfContingentConsiderationPayableToSellers	0	USD
CY2016	rtrx	Present Value Of Contingent Consideration Payable To Sellers PresentValueOfContingentConsiderationPayableToSellers	0	USD
CY2015	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2016	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2015Q4	rtrx	Purchase Obligation Duein Rolling Year Fourand Five PurchaseObligationDueinRollingYearFourandFive	0	USD
CY2015Q4	rtrx	Purchase Obligation Duein Rolling Year Twoand Three PurchaseObligationDueinRollingYearTwoandThree	150000	USD
CY2015Q4	rtrx	Purchase Obligation Duein Rollingafter Year Five PurchaseObligationDueinRollingafterYearFive	0	USD
CY2015Q4	rtrx	Purchase Obligation Next Rolling Twelve Months PurchaseObligationNextRollingTwelveMonths	2591000	USD
CY2014	rtrx	Purchaseof Companyinexchangeforfutureconsideration PurchaseofCompanyinexchangeforfutureconsideration	1000000	USD
CY2015	rtrx	Purchaseof Companyinexchangeforfutureconsideration PurchaseofCompanyinexchangeforfutureconsideration	0	USD
CY2016	rtrx	Purchaseof Companyinexchangeforfutureconsideration PurchaseofCompanyinexchangeforfutureconsideration	0	USD
CY2014	rtrx	Reclassification Of Derivative Liabilities To Equity ReclassificationOfDerivativeLiabilitiesToEquity	2500000	USD
CY2016	rtrx	Reclassification Of Derivative Liabilities To Equity ReclassificationOfDerivativeLiabilitiesToEquity	2500000	USD
CY2014	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	23365000	USD
CY2015	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	23537000	USD
CY2016	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	14715000	USD
CY2015	rtrx	Releaseof Accrued Severance Amounts ReleaseofAccruedSeveranceAmounts	2126000	USD
CY2014	rtrx	Securities Sold Not Yet Purchased1 SecuritiesSoldNotYetPurchased1	7500000	USD
CY2015	rtrx	Securities Sold Not Yet Purchased1 SecuritiesSoldNotYetPurchased1	0	USD
CY2016	rtrx	Securities Sold Not Yet Purchased1 SecuritiesSoldNotYetPurchased1	0	USD
CY2014	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	0	USD
CY2015	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	15844000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7639000	USD
CY2016	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	0	USD
CY2014Q1	rtrx	Underwriting Fees And Other Offering Costs UnderwritingFeesAndOtherOfferingCosts	3164990	USD
CY2015Q1	rtrx	Underwriting Fees And Other Offering Costs UnderwritingFeesAndOtherOfferingCosts	9181991	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7522000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12458000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18510000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23820000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33308000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7143000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7441000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-682000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-490000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365802000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	421309000	USD
CY2014	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	0	USD
CY2015	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2461000	USD
CY2016	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1976000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	359000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	2425000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15900000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25900000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29102000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	398000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1097000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4708000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1084000	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1340000	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5278000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13231000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15993000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4216355	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3736992	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9373686	shares
CY2015Q4	us-gaap	Assets Assets	512264000	USD
CY2016Q4	us-gaap	Assets Assets	525282000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	301932000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	332352000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	191799000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	214871000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	651000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	550000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	192442000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	215414000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	191799000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	214871000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	2300000	USD
CY2015	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-300000	USD
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	13778000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	18383000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5997000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18204000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37805000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12207000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19601000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3197000	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36465853	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37906669	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36465853	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37906669	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1 vote
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106542000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	112270000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47711000	USD
CY2015Q4	us-gaap	Contractual Obligation ContractualObligation	84653000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	43766000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	44422000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	571000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2185000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4554000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2094000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	13137000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3803000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12982000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1709000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2870000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1832000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	30000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-155000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1886000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8296000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-18814000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2460000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15573000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22661000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	54437000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	48700000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-574000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7277000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3847000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37089000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57855000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	60000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9484000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18520000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3160000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4621000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6980000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15600000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15580000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	24328000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6425000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	25124000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	34153000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	24328000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6425000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.43
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.78
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.17
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5401000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13392000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16135000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	38810000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	22440000	USD
CY2014	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1881000	USD
CY2016	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.43
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.46
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.95
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.49
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-10000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	117000	USD
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0223
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1100
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1835
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2663
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2702
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1630
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0551
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0153
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0316
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	161536000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	156543000	USD
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0785
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.1040
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0115
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0368
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0205
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0677
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0158
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2425000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-359000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	23786000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	33307000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1655000	USD
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17560000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33497000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	72148000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	16879000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16879000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	16879000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	16879000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	16879000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	140004000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-40000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	93000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	900000	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-112000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-62000	USD
CY2014	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2015	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	15500000	USD
CY2016	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4151000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	4700000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4710000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113398000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-366000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25512000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	144339000	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12994000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	105467000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6146000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20795000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30646000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12287000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57582000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2460000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-40021000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38761000	USD
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10525000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11770000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5070000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7392000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6467000	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3684000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9679000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	5000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	9610000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	7933000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	20604000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3379000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9672000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7959000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4504000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6090000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	282000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1174000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	105578000	USD
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	179096000	USD
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215540000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	161536000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	182043000	USD
CY2014	us-gaap	Interest Expense InterestExpense	7400000	USD
CY2015	us-gaap	Interest Expense InterestExpense	7700000	USD
CY2016	us-gaap	Interest Expense InterestExpense	800000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86981000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-2469000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	306000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	966000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2447000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	0	USD
CY2015	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	8107000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-4644000	USD
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2642160	shares
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7435000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7748000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-759000	USD
CY2014	us-gaap	Interest Paid InterestPaid	4080000	USD
CY2015	us-gaap	Interest Paid InterestPaid	5838000	USD
CY2016	us-gaap	Interest Paid InterestPaid	2070000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2247000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1490000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	2536000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	2826000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	289000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1336000	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	212293000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	217515000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	512264000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	525282000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	83262000	USD
CY2014	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2015	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2016	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
CY2015Q4	us-gaap	Loss Contingency Damages Sought LossContingencyDamagesSought	5
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	191799000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	214871000	USD
CY2014	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	2349000	USD
CY2015	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-293000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	117237000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	11216000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-13403000	USD
CY2016	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2014	us-gaap	Operating Expenses OperatingExpenses	108011000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	25476000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	191805000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-79808000	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2210000	USD
CY2016	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	8000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95320000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100767000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5694000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-37263000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	156215000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14387000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8104000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6944000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20496000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-37113000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-8603000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-47903000	USD
CY2014	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-110938000	USD
CY2015	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	119118000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-49558000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33590000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9416000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10274000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-15204000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-50748000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7738000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18568000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5935000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	632000	USD
CY2015Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46849000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46849000	USD
CY2015Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	45573000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8241000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11379000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-80602000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	10370000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20372000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-45850000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-554000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1596000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-110938000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	39655000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-25527000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-18222000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	164835000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	31012000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	48501000	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	45651000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	150640000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	37249000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	44690000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54317000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	55549000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-58214000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10861000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling After Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	3448000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four And Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFourAndFive	2491000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two And Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwoAndThree	2870000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	2052000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1859000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7364000	USD
CY2014	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4396000	USD
CY2015	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4927000	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	99000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4395000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4927000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	99000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	958000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1842000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3066000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4010000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2352000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-296000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-264000	USD
CY2014	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3165000	USD
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	9500000	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2257000	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29150000	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	33430000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3301000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7008000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10496000	USD
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	400000	USD
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2016	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10149000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	198530000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	184111000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	663000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1428000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2378000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4831000	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	8107000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3463000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149487000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	8398000	USD
CY2015	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4475000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6005000	USD
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	42366000	USD
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2016	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	42924000	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6493000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9977000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159520000	USD
CY2014	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	148411000	USD
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6818000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4016000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	428000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2587000	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2015Q4	us-gaap	Purchase Obligation PurchaseObligation	2741000	USD
CY2014	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2015	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	45000000	USD
CY2016	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	31283000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	500000	USD
CY2015	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	2000000	USD
CY2016	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47795000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50426000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70853000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65153000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113056000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28203000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17372000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24068000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28005000	USD
CY2015Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	30447000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	299971000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	307767000	USD
CY2016Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	61000	USD
CY2015	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-40000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	99892000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	29008000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33311000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33945000	USD
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37327000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	133591000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59645000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79541000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	92803000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	15900000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	25900000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	29102000	USD
CY2015Q4	us-gaap	Share Price SharePrice	19.29
CY2016Q4	us-gaap	Share Price SharePrice	18.93
CY2015Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	19.00
CY2014Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.50
CY2015	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	6818000	USD
CY2016	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	4016000	USD
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15844000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4708000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36836000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139987000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16639000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	25900000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29102000	USD
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2258000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-19667000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-37251000	USD
CY2016	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	96000	USD
CY2015	us-gaap	Treasury Stock Retired Par Value Method Amount TreasuryStockRetiredParValueMethodAmount	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3324000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1824000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1424000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	400000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8600000	USD
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25057509	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37581439	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38288012	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25057509	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33560249	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36997865	shares
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#4c4c4c;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on the development, acquisition and commercialization of therapies for the treatment of serious or rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">We are currently developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan is an investigational therapeutic agent which acts as both a potent ARB, as well as a selective ERA, with in vitro selectivity toward endothelin receptor type A. The Company has secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for FSGS, which is a leading cause of end-stage renal disease and NS. Sparsentan was granted orphan drug designation in the United States and the European Union in January 2015 and November 2015, respectively. In the third quarter of 2016, the Company announced positive top-line data from the Phase 2 DUET study of sparsentan for the treatment of FSGS. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In early 2017, we had</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">an End of Phase 2 meeting with the FDA regarding the regulatory pathway for sparsentan as a treatment for FSGS.  Following the meeting and our receipt of confirmatory meeting minutes, we announced our plans to initiate a single Phase 3 clinical trial to serve as the basis of a New Drug Application ("NDA") filing for sparsentan for the treatment of FSGS.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Fosmetpantotenate</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, also known as RE-024, a novel small molecule, is being developed as a potential treatment for pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include parkinsonism, dystonia, and other severe systemic manifestations. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Fosmetpantotenate (RE-024) is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients. Certain international health regulators have approved the initiation of dosing fosmetpantotenate (RE-024) in PKAN patients under physician-initiated studies in accordance with local regulations in their respective countries. The Company filed a U.S. IND for fosmetpantotenate (RE-024) with the FDA in the first quarter of 2015 to support the commencement of a Company-sponsored Phase 1 study, which was successfully completed during 2015. The FDA granted fosmetpantotenate (RE-024) orphan drug designation in May 2015 and fast track designation in June 2015. In February, 2016, the Company announced fosmetpantotenate (RE-024) was granted orphan drug designation by the European Commission. In November, 2016, the Company announced that it had reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating fosmetpantotenate (RE-024) for PKAN. The Company expect to begin dosing patients in this Phase 3 clinical trial in the coming months. The Company continues discussions with the EMA regarding the initiation of a potential registration-enabling efficacy trial in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Tetracosactide zinc (RE-034) is a synthetic hormone analog of the first 24 amino acids of the 39 amino acids contained in adrenocorticotropic hormone ("ACTH") incorporated into a novel formulation developed by us. Tetracosactide zinc (RE-034) exhibits similar physiological actions as endogenous ACTH by binding to all five melanocortin receptors (pan-MCR), resulting in its anti-inflammatory and immunomodulatory effects. The Company successfully manufactured tetracosactide zinc (RE-034) at proof-of-concept scale using a novel formulation process that allows modulation of the release of the active ingredient from the site of administration. The Company decided to focus our further efforts on this program toward an external partnership and out-licensing opportunities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). We obtained L-UDCA during 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">We currently sell the following </font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for CTX patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior year financial statements in order to conform to the current year’s presentation.</font></div></div>
CY2016	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Patents</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company expenses external costs, such as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company also expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the fair value of net assets acquired in business combinations, estimating the useful lives of depreciable and amortizable assets, goodwill impairment, estimating of contingent consideration, estimating of valuation allowances and uncertain tax positions, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</font></div></div>

Files In Submission

Name	View Source	Status
0001438533-17-000005-index-headers.html	Edgar Link	pending
0001438533-17-000005-index.html	Edgar Link	pending
0001438533-17-000005.txt	Edgar Link	pending
0001438533-17-000005-xbrl.zip	Edgar Link	pending
exhibit1034-1231201610k.htm	Edgar Link	pending
exhibit211-1231201610k.htm	Edgar Link	pending
exhibit231-1231201610kxbdo.htm	Edgar Link	pending
exhibit311-1231201610k.htm	Edgar Link	pending
exhibit312-1231201610k.htm	Edgar Link	pending
exhibit321-1231201610k.htm	Edgar Link	pending
exhibit322-1231201610k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
rppipelinechart.jpg	Edgar Link	pending
rtrx-20161231.xml	Edgar Link	completed
rtrx-20161231.xsd	Edgar Link	pending
rtrx-20161231x10k.htm	Edgar Link	pending
rtrx-20161231_cal.xml	Edgar Link	unprocessable
rtrx-20161231_def.xml	Edgar Link	unprocessable
rtrx-20161231_lab.xml	Edgar Link	unprocessable
rtrx-20161231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
stockpriceperformance.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2016 Form 10-K Financial Statement

#000143853317000005 Filed on March 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2016 Form 10-K Financial Statement

#000143853317000005 Filed on March 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx